Mediterr J Rheumatol 2016;27(2):75-7
Levels of miRNA miR200b-5p (miR200b*) in the minor salivary glands (MSG) of patients with Sjögren’s syndrome: Possible prognostic value for future lymphoma development?
Authors Information

Pathophysiology Dept., School of Medicine, National and Kapodistrian University of Athens, Greece & Academic Joint Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens, Greece

  1. Tzioufas A G, Kapsogeorgou E K, Moutsopoulos H M. Pathogenesis of Sjögren’s syndrome: what we know and what we should learn. J Autoimmun 2012;39:4-8.
  2. Christodoulou M I, Kapsogeorgou E K, Moutsopoulos H M. Characteristics of the minor salivary gland infiltrates in Sjögren’s syndrome. J Autoimmun 2010;34:400-7.
  3. Manoussakis M N, Boiu S, Korkolopoulou P, Kapsogeorgou E K, Kavantzas N, Ziakas P, et al. Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjögren’s syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum 2007;56:3977-88.
  4. Theander E, Vasaitis L, Baecklund E, Nordmark G, Warfvinge G, Liedholm R, et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren’s syndrome. Ann Rheum Dis 2011;70:1363-8.
  5. Gerli R, Muscat C, Giansanti M, Danieli M G, Sciuto M, Gabrielli A, et al. Quantitative assessment of salivary gland inflammatory infiltration in primary Sjögren’s syndrome: its relationship to different demographic, clinical and serological features of the disorder. Br J Rheumatol 1997;36:969-75.
  6. Kapsogeorgou E K, Christodoulou MI, Panagiotakos D B, Paikos S, Tassidou A, Tzioufas A G, et al. Minor salivary gland inflammatory lesions in Sjögren’s syndrome: do they evolve? J Rheumatol 2013;40:1566-71.
  7. Winter J, Jung S, Keller S, Gregory R I, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009;11:228-34.
  8. Pauley K M, Cha S, Chan E K. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun 2009;32:189-94.
  9. Alevizos I, Alexander S, Turner R J, Illei G G. MicroRNA expression profiles as biomarkers of minor salivary gland inflammation and dysfunction in Sjögren’s syndrome. Arthritis Rheum 2011;63:535-44.
  10. Gourzi V C, Kapsogeorgou E K, Kyriakidis N C, Tzioufas A G. Study of microRNAs (miRNAs) that are predicted to target the autoantigens Ro/SSA and La/SSB in primary Sjögren’s Syndrome. Clin Exp Immunol 2015;182:14-22.
  11. Feng B, Wang R, Chen L B. Review of miR-200b and cancer chemosensitivity. Biomed Pharmacother 2012;66:397-402.
  12. Hummel R, Hussey D J, Haier J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer 2010;46:298-311.
  13. Sun L, Yao Y, Liu B, Lin Z, Lin L, Yang M, et al. MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene 2012;31:432-45.